ALZAMEND NEURO
Alzamend Neuro is an innovative biotechnology company that develops and commercializes drugs, treatments, and cures for Alzheimer's disease. The company also focused on the facilitation of bringing technologies to market which help with the treatment, prevention, or cure of Alzheimer’s. They providing hope through the commercialization of existing patented intellectual property while simultaneously funding future treatments through advanced research and development. Alzamend Neuro was founded in 2016 and is headquartered in Newport Beach, CA, USA.
ALZAMEND NEURO
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
2016-01-01
Address:
Newport Beach, California, United States
Country:
United States
Website Url:
http://www.alzamend.com
Status:
Active
Contact:
(844) 722-6333
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Font Awesome
Similar Organizations
Cytodiagnostics
Cytodiagnostics is a biotechnology company and developing nanotechnology derived products and services for life science research.
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
OvaGene Oncology
OvaGene is an in-revenue growth company that develops and commercializes Molecular Diagnostics for women.
Precise Bio
Precise Bio is a regenerative medicine company that develops and commercializes 4D bio-fabricated functional tissues and organs.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.alzamend.com
- Host name: ecngx318.inmotionhosting.com
- IP address: 70.39.144.94
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "Alzamend Neuro"
Corporate Overview – Alzamend Neuro
Alzamend Neuro® , Inc., (“Alzamend® ”), a Delaware corporation with its headquarters in Atlanta, Georgia, is a clinical-stage, biopharmaceutical company. At Alzamend, we are committed to …See details»
Alzamend Neuro - Crunchbase Company Profile
Alzamend Neuro is an innovative biotechnology company that develops and commercializes drugs, treatments, and cures for Alzheimer's disease. The company also focused on the facilitation of bringing technologies to market …See details»
Alzamend Neuro - LinkedIn
Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder …See details»
Alzamend Neuro Partners with Massachusetts General Hospital for …
ATLANTA, August 19, 2024--Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of …See details»
Alzamend Neuro Company Profile - Craft
Jul 12, 2024 Alzamend Neuro is a biopharmaceutical company developing treatments for neurodegenerative diseases and psychiatric disorders. It offers mutant-peptide …See details»
Alzamend Neuro Partners with Massachusetts General Hospital for …
Aug 12, 2024 ATLANTA--(BUSINESS WIRE)-- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel …See details»
Alzamend Neuro Announces Closing of Initial Public Offering and …
Jun 17, 2021 Tampa, FL – (Business Newswire – June 17, 2021) – Alzamend Neuro, Inc. (“Alzamend”), a preclinical stage biopharmaceutical company focused on developing novel …See details»
Alzamend Neuro Receives FDA "Study May Proceed" Notification …
ATLANTA, November 20, 2023--Alzamend Gets FDA "Study May Proceed" Notice for Phase IIA Clinical Trial of AL001 a Next-Generation Lithium Therapeutic for Major Depressive DisorderSee details»
Alzamend Neuro Partners with Massachusetts General
Aug 6, 2024 All filings are available at www.sec.gov and on Alzamend’s website at www.Alzamend.com. Email: [email protected] or call: 1-844-722-6333 View source version …See details»
Alzamend Neuro Receives FDA “Study May Proceed” Notification …
Nov 20, 2023 According to the World Health Organization, approximately 280 million people (3.8% of the world’s population) in the world suffer from MDD. About Alzamend Neuro. …See details»
Alzamend Neuro Announces Full Data Set from its Nonclinical
Nov 19, 2024 Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’ s disease, bipolar disorder, major …See details»
Alzamend Neuro Submits IND Application for a Phase IIA Clinical …
Oct 23, 2023 According to the World Health Organization, approximately 280 million people (3.8% of the world’s population) in the world suffer from MDD. About Alzamend NeuroSee details»
Company Information :: Alzamend Neuro, Inc. (ALZN)
Company Contact Alzamend Neuro, Inc. 3480 Peachtree Road NE Second Floor, Suite 103 Atlanta, GA 30326 T: 844-722-6333See details»
Featured – Alzamend Neuro
Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s. Data confirm the positive topline results …See details»
Alzamend Neuro Partners with Massachusetts General Hospital for …
Aug 19, 2024 Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission …See details»
Alzamend Neuro (ALZN) Earnings Date and Reports 2025
6 days ago Alzamend Neuro released Q1 2025 earnings on September 11, 2024, reporting an EPS of -$1.25, which topped analysts' consensus estimates of -$2.38 by $1.13. With a trailing …See details»
Alzamend Neuro Partners with Massachusetts General Hospital for …
Aug 12, 2024 Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission …See details»
News – Alzamend Neuro
In February 2016, Mr. Ault founded Alzamend Neuro, Inc., a biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major …See details»
Alzamend Neuro Announces Full Data Set From Phase 1 First-in …
Mar 28, 2022 ATLANTA--(BUSINESS WIRE)-- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel …See details»